exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087911 RNA Name: hsa-miR-21-5p RNA Type: miRNA Chromosome: chr17 Starnd: + Coordinate: Start Site(bp): 59841273 End Site(bp): 59841294 External Links: hsa-miR-21-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand KAZN chr1 13892792 15118043 + UBE2T chr1 202331657 202341980 - CLEC2D chr12 9664969 9699553 + EIF4A2 chr3 186783205 186789897 + MGST1 chr12 16347142 16609259 + POLE3 chr9 113407235 113410675 - SOWAHC chr2 109614364 109618990 + OSER1 chr20 44195939 44210771 - EXOC4 chr7 133253073 134066589 + EDARADD chr1 236348257 236502915 + HNRNPA0 chr5 137745651 137754363 - GPSM3 chr6 32190766 32195523 - CTH chr1 70411218 70439851 + CITED2 chr6 139371807 139374648 - MTREX chr5 55307989 55425579 + AP3D1 chr19 2100988 2164468 - ELP2 chr18 36129444 36180557 + HSPA4 chr5 133052013 133106449 + RGS1 chr1 192575763 192580024 + HSD17B4 chr5 119452473 119637199 + ZFP36L1 chr14 68787660 68796253 - HMGA1 chr6 34236873 34246231 + EEF1B2 chr2 206159585 206162928 + DYNC1H1 chr14 101964573 102056443 + DUSP2 chr2 96143169 96145440 - MCRS1 chr12 49556544 49568145 - ATRX chrX 77504878 77786233 - ZADH2 chr18 75195113 75209139 - PLIN2 chr9 19108375 19149290 - TREX1 chr3 48465811 48467645 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001731 chr7 100731990 100738448 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC068768.1 chr12 123262060 123262402 + ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - OTUD6B-AS1 chr8 91059318 91070583 - SNHG1 chr11 62851984 62855953 - TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.